XOMA Royalty Declares Quarterly Preferred Stock Dividends

Rhea-AI Summary

XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividend payments for its preferred stockholders. The company's Board of Directors has authorized dividends for two series of preferred stock:

- Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share

- Holders of 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share, with each depositary share representing 1/1000 of a preferred share

Both dividend payments are scheduled for April 15, 2025, with a record date of April 3, 2025.

Positive

• Consistent dividend payments maintained for preferred stockholders
• Attractive dividend yields: 8.625% for Series A and 8.375% for Series B preferred stocks

Negative

• None.

EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:

Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. 

Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.

The preferred dividends will be paid on or about April 15, 2025, to respective holders of record at the close of business on April 3, 2025.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY^® [coagulation factor IX (recombinant)], and DSUVIA^® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

Investor contact: Juliane Snowden XOMA Royalty Corporation +1-646-438-9754 juliane.snowden@xoma.com

Media contact: Kathy Vincent KV Consulting & Management +1-310-403-8951 kathy@kathyvincent.com

                                                                                              
                                                                               

FAQ

What is the dividend amount for XOMA Series A preferred stock (XOMAP) in Q2 2025?

XOMA Series A preferred stockholders (XOMAP) will receive a cash dividend of $0.53906 per share for Q2 2025.

When is the payment date for XOMA's preferred stock dividends announced in March 2025?

The preferred stock dividends will be paid on April 15, 2025, to holders of record as of April 3, 2025.

What is the dividend amount for XOMA Series B preferred stock (XOMAO) depositary shares?

XOMA Series B preferred stock (XOMAO) depositary shareholders will receive $0.52344 per depositary share.

What are the dividend yields for XOMA's Series A and Series B preferred stocks?

The Series A preferred stock (XOMAP) has an 8.625% yield, while the Series B preferred stock (XOMAO) has an 8.375% yield.